MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's clinical development pipeline includes lead drug candidate Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor. Pracinostat has been tested in more than 150 patients in multiple Phase I and exploratory Phase II clinical trials, including advanced hematologic malignancies such as myelodysplastic syndrome, acute myeloid leukemia and myelofibrosis. The Company expects to initiate a randomized Phase II trial of Pracinostat in combination with standard-of-care in at least one hematologic malignancy toward the middle of 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. Results from a Phase I trial of intravenous ME-143 in heavily treated patients with solid refractory tumors were presented at the American Society of Clinical Oncology Annual Meeting in June 2012. A Phase I clinical trial of intravenous ME-344 in patients with solid refractory tumors is ongoing.MEI Pharma is a small health care company based in San Diego, CA with only 40 employees and an annual revenue of $48.0M.
MEI Pharma's Mission Statement
To develop and commercialize novel, best-in-class, cancer therapies intended to improve outcomes for patients.
In demand companies are hiring!
Let us apply for you!
-
MEI Pharma employee reviews
Be the first to review!
Do you work at MEI Pharma?
Help job seekers learn about working at MEI Pharma
Zippia gives an in-depth look into the details of MEI Pharma, including salaries, political affiliations, employee data, and more, in order to inform job seekers about MEI Pharma. The employee data is based on information from people who have self-reported their past or current employments at MEI Pharma. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by MEI Pharma. The data presented on this page does not represent the view of MEI Pharma and its employees or that of Zippia.
MEI Pharma may also be known as or be related to MEI PHARMA INC., MEI Pharma, MEI Pharma Inc, MEI Pharma, Inc. and Mei Pharma.